Sex: M
Vaccine: COVID19
Symptoms: Vascular resistance systemic, Ventilation/perfusion scan
Clinical narrative: Pulmonary Hypertension; This is a literature report.  A 56-year-old male patient received BNT162b2 (BNT162B2), in Apr2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "non-smoker" (unspecified if ongoing); "spontaneous deep venous thrombosis" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), administration date: Apr2021, for COVID-19 Immunisation. The following information was reported: PULMONARY HYPERTENSION (medically significant, life threatening) with onset 2021, 12 days after the suspect product(s) administration, outcome "unknown". The patient underwent the following laboratory tests and procedures: Blood pressure systolic: (unspecified date) normal; Body mass index: (unspecified date) 25; Brain natriuretic peptide: (unspecified date) 99 pg/mL, notes: remained in normal range; Computerised tomogram thorax: (unspecified date) revealed mosaic attenuation of lung parenchyma, notes: with relative pruning of distal pulmonary vessels and mild enlargement of the PA without evidence of pulmonary emboli; Echocardiogram: (2005) normal; Ejection fraction: (unspecified date) 60 %; Haematology test: (unspecified date) identified no clotting abnormalities.; Evidence of Pulmonary Clots: (unspecified date) None; (Sep2021) 2.82, notes: Units: m/s; performed 5 months after vaccination; (Dec2021) 3.22, notes: Units: m/s; three months later; (Jul2022) 3.22, notes: Units: m/s; Fifteen months after vaccination; (unspecified date) negative for twelve genetic predisposition markers, notes; Magnetic resonance imaging heart: (unspecified date) revealed a mildly enlarged right ventricle with, notes: normal systolic function and normal main PA; (2005) an incidental isolated left superior vena cava was, notes: was suspected by an otherwise normal transthoracic echocardiogram and confirmed by cardiac magnetic resonance imaging; NYHA classification: (unspecified date) 2; Pulmonary arterial pressure: (unspecified date) normal; Pulmonary arterial pressure: (unspecified date) 44/18 mmHg, notes: mean 28 mm Hg; Right ventricular systolic pressure: (Sep2021) 40 mmHg, notes: performed 5 months after vaccination; (Dec2021) 46 mmHg, notes: three months later; (Jul2022) 49 mmHg, notes: Fifteen months after vaccination; SARS-CoV-2 test: (unspecified date) negative at the time of the onset of these symptom; Stress echocardiogram: (unspecified date) revealed normal left ventricular, notes: function, an ejection fraction (EF) of 60%, ventricular ectopy and mild right-sided chamber enlargement. No right-sided pressures were measured; Vascular resistance systemic: (unspecified date) 3.6, notes: Units: Woods units; Ventilation/perfusion scan: (unspecified date) was interpreted as near normal and a very low, notes: probability for pulmonary emboli. Therapeutic measures were taken as a result of pulmonary hypertension.; Sender's Comments: Based on the information available, a possible contributory role of the suspect drug for the reported event Pulmonary hypertension cannot be excluded. This impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly to regulatory authorities, Ethics Committees, and Investigators, as appropriate. ,Linked Report(s) : US-PFIZER INC-PV202300151257 Same article/ drug/event and different patient:;